BMRN · Biomarin Pharmaceutical Inc - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $3.22B | $2.85B | $2.42B | $2.10B | $1.85B | $1.86B |
| Cost of Revenue | $717.44M | $580.24M | $514.85M | $483.67M | $470.51M | $524.27M |
| Gross Profit | $2.50B | $2.27B | $1.90B | $1.61B | $1.38B | $1.34B |
| R&D | $921.93M | $747.18M | $746.77M | $649.61M | $628.79M | $628.12M |
| SG&A | $1.15B | $1.01B | $937.29M | $854.01M | $759.38M | $737.67M |
| Total Operating Expenses | $2.81B | $2.37B | $2.26B | $1.95B | $1.93B | $1.90B |
| D&A | $79.56M | $96.43M | $104.39M | $101.97M | $108.04M | $105.17M |
| Operating Income | $409.48M | $484.21M | $158.10M | $149.56M | ($82.34M) | ($36.77M) |
| Interest Expense | $10.90M | $12.67M | $17.34M | $15.97M | $15.34M | $29.31M |
| Income Tax | $133.58M | $114.90M | $20.92M | $8.02M | ($11.27M) | ($901.42M) |
| Net Income | $348.90M | $426.86M | $167.65M | $141.56M | ($64.08M) | $859.10M |
| EPS - Basic | $1.82 | $2.25 | $0.89 | $0.76 | ($0.35) | $4.75 |
| EPS - Diluted | $1.80 | $2.21 | $0.87 | $0.75 | ($0.35) | $4.53 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.31B | $942.84M | $755.13M | $724.53M | $587.28M | $649.16M |
| Accounts Receivable | $908.21M | $660.53M | $633.70M | $461.32M | $373.40M | $448.35M |
| Inventory | $1.30B | $1.23B | $1.11B | $894.08M | $776.67M | $698.55M |
| Accounts Payable | - | - | - | - | - | - |
| Current Assets | $3.95B | $3.23B | $2.96B | $2.75B | $2.27B | $2.34B |
| Total Assets | $7.59B | $6.99B | $6.84B | $6.38B | $6.00B | $5.85B |
| Current Liabilities | $759.03M | $606.99M | $1.18B | $588.88M | $539.82M | $492.55M |
| Long-term Debt | - | - | - | - | - | - |
| Total Liabilities | $1.51B | $1.33B | $1.89B | $1.77B | $1.73B | $1.74B |
| Stockholders' Equity | $6.09B | $5.66B | $4.95B | $4.60B | $4.27B | $4.11B |
| Retained Earnings | $154.21M | ($194.69M) | ($621.55M) | ($789.20M) | ($925.69M) | ($861.61M) |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $827.99M | $572.84M | $159.26M | $175.90M | $304.54M | $85.36M |
| Investing Cash Flow | ($414.24M) | $136.49M | ($111.24M) | ($20.03M) | ($366.31M) | ($53.62M) |
| Financing Cash Flow | ($42.39M) | ($526.45M) | ($18.73M) | ($18.65M) | ($48.0K) | $181.12M |
| CapEx | $103.04M | $85.42M | $96.69M | $120.96M | $95.58M | $114.31M |
| Free Cash Flow | $724.96M | $487.42M | $62.57M | $54.94M | $208.96M | ($28.95M) |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 77.7% | 79.7% | 78.7% | 76.9% | 74.5% | 71.8% |
| Operating margin | 12.7% | 17.0% | 6.5% | 7.1% | -4.5% | -2.0% |
| EBITDA margin | 15.2% | 20.3% | 10.8% | 12.0% | 1.4% | 3.7% |
| Net margin | 10.8% | 15.0% | 6.9% | 6.8% | -3.5% | 46.2% |
| Free cash flow margin | 22.5% | 17.1% | 2.6% | 2.6% | 11.3% | -1.6% |
| FCF / Net income | 2.08 | 1.14 | 0.37 | 0.39 | -3.26 | -0.03 |
| R&D / Revenue | 28.6% | 26.2% | 30.9% | 31.0% | 34.1% | 33.8% |
| SG&A / Revenue | 35.8% | 35.4% | 38.7% | 40.7% | 41.1% | 39.6% |
| Effective tax rate | 27.7% | 21.2% | 11.1% | 5.4% | - | - |
| Return on assets | 4.6% | 6.1% | 2.5% | 2.2% | -1.1% | 14.7% |
| Return on equity | 5.7% | 7.5% | 3.4% | 3.1% | -1.5% | 20.9% |
| Return on invested capital | - | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 5.21 | 5.33 | 2.51 | 4.67 | 4.21 | 4.76 |
| Quick ratio | 3.50 | 3.29 | 1.57 | 3.15 | 2.77 | 3.34 |
| Cash ratio | 1.73 | 1.55 | 0.64 | 1.23 | 1.09 | 1.32 |
| Leverage | ||||||
| Debt / Equity | - | - | - | - | - | - |
| Debt / Assets | - | - | - | - | - | - |
| Debt / EBITDA | - | - | - | - | - | - |
| Interest coverage | 37.6x | 38.2x | 9.1x | 9.4x | -5.4x | -1.3x |
| Equity multiplier | 1.25 | 1.24 | 1.38 | 1.38 | 1.41 | 1.42 |
| Liabilities / Assets | 0.20 | 0.19 | 0.28 | 0.28 | 0.29 | 0.30 |
| Efficiency | ||||||
| Asset turnover | 0.42 | 0.41 | 0.35 | 0.33 | 0.31 | 0.32 |
| Inventory turnover | 0.55 | 0.47 | 0.47 | 0.54 | 0.61 | 0.75 |
| Days sales outstanding | 103d | 84d | 96d | 80d | 74d | 88d |
| Days inventory outstanding | 661d | 775d | 785d | 675d | 602d | 486d |
| Days payable outstanding | - | - | - | - | - | - |
| Cash conversion cycle | - | - | - | - | - | - |
| Valuation | ||||||
| P / E | 33.0x | 29.7x | 110.8x | 138.0x | - | 19.4x |
| P / B | 1.9x | 2.3x | 3.7x | 4.2x | 3.8x | 4.1x |
| P / S | 3.6x | 4.5x | 7.6x | 9.3x | 8.8x | 9.0x |
| EV / EBITDA | 21.3x | 20.6x | 67.5x | 74.9x | 605.8x | 236.2x |
| Growth | ||||||
| Revenue growth (YoY) | 12.9% | 18.0% | 15.4% | 13.5% | -0.8% | 9.2% |
| Revenue CAGR (3y) | 15.4% | 15.6% | 9.1% | 7.1% | 18.2% | 12.3% |
| Revenue CAGR (5y) | 11.6% | 10.9% | 16.7% | 9.8% | 10.6% | 15.9% |
| Gross profit growth (YoY) | 10.1% | 19.4% | 18.1% | 17.2% | 3.0% | -0.6% |
| Operating income growth (YoY) | -15.4% | 206.3% | 5.7% | - | -124.0% | 63.4% |
| Net income growth (YoY) | -18.3% | 154.6% | 18.4% | - | - | - |
| EPS growth (YoY) | -18.6% | 154.0% | 16.0% | - | - | - |
| EPS CAGR (3y) | 33.9% | - | -42.3% | - | - | - |
| EPS CAGR (5y) | -16.9% | - | - | - | - | - |
| FCF growth (YoY) | 48.7% | 679.0% | 13.9% | -73.7% | - | 70.1% |
| FCF CAGR (5y) | - | - | - | - | - | - |
| Book value growth (YoY) | 7.6% | 14.3% | 7.6% | 7.8% | 4.0% | 31.5% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2025-12-31.
Business segments
$3.22B totalReportable Segment$3.22B · 100.0%
Product / service
$7.49B totalProduct$3.17B · 42.3%
Products Excluding ALDURAZYME$1.10B · 14.7%
VOXZOGO$926.92M · 12.4%
VIMIZIM$792.05M · 10.6%
NAGLAZYME$485.40M · 6.5%
PALYNZIQ$433.31M · 5.8%
ALDURAZYME$208.51M · 2.8%
BRINEURA$186.40M · 2.5%
KUVAN$99.53M · 1.3%
Royalty And Other$53.49M · 0.7%
ROCTAVIAN$35.64M · 0.5%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
2.61
Grey zone
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
5/9
Neutral
- ✓Net income positive
- ✓Operating cash flow positive
- ✗ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✗Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Pharmaceutical Preparations
Comparing BIOMARIN PHARMACEUTICAL INC against the 5 most active filers in the same SIC group.